Semaglutide vs Survodutide: GLP-1 vs GLP-1/Glucagon Dual Agonist
Compare semaglutide vs survodutide for weight loss and MASH treatment. How the GLP-1/glucagon dual mechanism differs from GLP-1 alone.
| Dimension | semaglutide | survodutide | Notes |
|---|---|---|---|
| Weight Loss | 15-17% | 18-19% | Survodutide Phase 2 showed up to 18.7% weight loss at 46 weeks. |
| Mechanism | GLP-1 only | GLP-1 + Glucagon | Survodutide adds glucagon for enhanced hepatic fat metabolism and thermogenesis. |
| FDA Status | Approved | Phase 3 trials | Semaglutide approved. Survodutide in Phase 3 for obesity and MASH. |
| Liver Benefits | Moderate | Strong | Survodutide shows significant MASH resolution — glucagon receptor drives liver fat reduction. |
| Side Effects | Well-documented | Limited data | GI effects expected with both. Survodutide safety profile still being characterized. |
Learn more about each peptide
Semaglutide
Semaglutide is a GLP-1 receptor agonist originally developed for type 2 diabetes that has demonstrated significant weight loss effects in clinical trials. It is sold under the brand names Ozempic (diabetes) and Wegovy (weight management).
Survodutide
Survodutide is a dual GLP-1/glucagon receptor agonist developed by Boehringer Ingelheim, currently in Phase 3 trials for obesity and metabolic liver disease.
More comparisons
Weekly peptide research updates
New studies, GLP-1 news, protocol insights, and weight loss data — delivered every week. Free. No spam.
Reviewed by Fat Man in the Arena · Updated March 2026
Medical Disclaimer: This comparison is for informational purposes only. Individual responses vary. Always consult a qualified healthcare provider before starting any peptide protocol.